Apnimed, Inc. (NASDAQ: APMD) is a Healthcare company (Biotechnology) with a market capitalization of $741M. The Maz Rating grades it against the other companies in its sector.
Apnimed, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $17.80, Apnimed, Inc. trades at 3.8x trailing earnings, 7.5x sales and 1.7x book value, with an EV/EBITDA of 17.5. Over the last twelve months it generated about $99M of revenue and $193M of net income. It runs a gross margin of 96.5%, an operating margin of 24.9% and a net margin of 172.1%. It shows return on equity of 136.6%, return on invested capital of 7.2% and a free cash flow yield of -8.0%. On the balance sheet: a debt-to-equity ratio of 0.14 and a current ratio of 9.77. Over the past 52 weeks the share price ranged from $13.88 to $35.29, with a beta of 7.95.
Apnimed, Inc. does not currently pay a dividend.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.